187 related articles for article (PubMed ID: 9652847)
1. Effect of filgrastim (G-CSF) during chemotherapy and abdomino-pelvic radiation therapy in patients with ovarian carcinoma.
Fyles AW; Manchul L; Levin W; Robertson JM; Sturgeon J; Tsuji D
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):843-7. PubMed ID: 9652847
[TBL] [Abstract][Full Text] [Related]
2. Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study.
Glisson B; Komaki R; Lee JS; Shin DM; Fossella F; Murphy WK; Kurie J; Perez-Soler R; Schea R; Vadhan-Raj S
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):331-6. PubMed ID: 9457817
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
4. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
Stahel RA; Jost LM; Cerny T; Pichert G; Honegger H; Tobler A; Jacky E; Fey M; Platzer E
J Clin Oncol; 1994 Sep; 12(9):1931-8. PubMed ID: 7521907
[TBL] [Abstract][Full Text] [Related]
5. A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide.
Weaver A; Wrigley E; Watson A; Chang J; Collins CD; Jenkins B; Gill C; Pettengell R; Dexter TM; Testa NG; Crowther D
Br J Cancer; 1996 Dec; 74(11):1821-7. PubMed ID: 8956800
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
Smith GM; Child JA; Cullen MH; Bailey NP; Woodruffe CM; Fletcher J; Earl H; Barnard D
Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465
[TBL] [Abstract][Full Text] [Related]
7. Dose escalation study of carboplatin and cyclophosphamide with filgrastim support: a phase I study.
Toner GC; Green M; Bishop JF; McKendrick J; Cebon J; Sheridan WP; Lockbaum P; O'Byrne J; Fox RM
Am J Clin Oncol; 1998 Jun; 21(3):263-9. PubMed ID: 9626795
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy for radiation-induced bone marrow aplasia in nonhuman primates using synthokine SC-55494 and recombinant human granulocyte colony-stimulating factor.
MacVittie TJ; Farese AM; Herodin F; Grab LB; Baum CM; McKearn JP
Blood; 1996 May; 87(10):4129-35. PubMed ID: 8639770
[TBL] [Abstract][Full Text] [Related]
10. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
Vose JM; Crump M; Lazarus H; Emmanouilides C; Schenkein D; Moore J; Frankel S; Flinn I; Lovelace W; Hackett J; Liang BC
J Clin Oncol; 2003 Feb; 21(3):514-9. PubMed ID: 12560443
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.
Gordon AN; Stringer CA; Matthews CM; Willis DL; Nemunaitis J
J Clin Oncol; 1997 May; 15(5):1965-73. PubMed ID: 9164208
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.
Veldhuis GJ; Willemse PH; Beijnen JH; Boonstra H; Piersma H; van der Graaf WT; de Vries EG
Br J Cancer; 1997; 75(5):703-9. PubMed ID: 9043028
[TBL] [Abstract][Full Text] [Related]
13. Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial.
Ottmann OG; Hoelzer D; Gracien E; Ganser A; Kelly K; Reutzel R; Lipp T; Busch FW; Schwonzen M; Heil G
Blood; 1995 Jul; 86(2):444-50. PubMed ID: 7541660
[TBL] [Abstract][Full Text] [Related]
14. An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma.
Michon JM; Hartmann O; Bouffet E; Meresse V; Coze C; Rubie H; Bordigoni P; Cattiaux E; Ward N; Bernard JL; Lemerle J; Zucker JM; Philip T
Eur J Cancer; 1998 Jun; 34(7):1063-9. PubMed ID: 9849455
[TBL] [Abstract][Full Text] [Related]
15. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
[TBL] [Abstract][Full Text] [Related]
16. Impact of Hematopoietic Growth Factors on Blood Transfusion Needs, Incidence of Neutropenia, and Overall Survival Among Elderly Advanced Ovarian Cancer Patients Treated With Chemotherapy.
Poonawalla IB; Piller LB; Lairson DR; Chan W; Du XL
Int J Gynecol Cancer; 2016 Jan; 26(1):95-103. PubMed ID: 26509851
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer.
Fanning J; Hilgers RD
Gynecol Oncol; 1996 Dec; 63(3):323-7. PubMed ID: 8946866
[TBL] [Abstract][Full Text] [Related]
19. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
[TBL] [Abstract][Full Text] [Related]
20. Filgrastim support during combination chemotherapy using cisplatin, doxorubicin, and cyclophosphamide to treat advanced or recurrent endometrial cancer: a clinical study and literature review.
Hall DJ; Martin DA; Kincaid K
Eur J Gynaecol Oncol; 2003; 24(6):481-9. PubMed ID: 14658586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
